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Abstract
Background: A quality assessment tool for diagnostic accuracy studies, named QUADAS, has
recently been developed. Although QUADAS has been used in several systematic reviews, it has
not been formally validated. The objective was to evaluate the validity and usefulness of QUADAS.
Methods: Three reviewers independently rated the quality of 30 studies using QUADAS. We
assessed the proportion of agreements between each reviewer and the final consensus rating. This
was done for all QUADAS items combined and for each individual item. Twenty reviewers who
had used QUADAS in their reviews completed a short structured questionnaire on their
experience of QUADAS.
Results: Over all items, the agreements between each reviewer and the final consensus rating
were 91%, 90% and 85%. The results for individual QUADAS items varied between 50% and 100%
with a median value of 90%. Items related to uninterpretable test results and withdrawals led to
the most disagreements. The feedback on the content of the tool was generally positive with only
small numbers of reviewers reporting problems with coverage, ease of use, clarity of instructions
and validity.
Conclusion:  Major modifications to the content of QUADAS itself are not necessary. The
evaluation highlighted particular difficulties in scoring the items on uninterpretable results and
withdrawals. Revised guidelines for scoring these items are proposed. It is essential that reviewers
tailor guidelines for scoring items to their review, and ensure that all reviewers are clear on how
to score studies. Reviewers should consider whether all QUADAS items are relevant to their
review, and whether additional quality items should be assessed as part of their review.
Background
QUADAS is a tool to assess the quality of diagnostic accu-
racy studies included in systematic reviews. We defined
quality as being concerned with both the internal and
external validity of a study. QUADAS was developed in a
systematic manner, based upon three reviews of existing
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evidence and a Delphi procedure involving a panel of
experts in diagnostic research [1]. Like all quality assess-
ment tools, QUADAS is a measurement, implying that its
characteristics have to be evaluated: does it measure what
it aims to measure, how well does it do this, and are
results reproducible between different observers [2]? The
objective of this study was to evaluate QUADAS by deter-
mining agreement between reviewers and the consensus
rating and variability among raters, and gathering feed-
back on reviewers' experiences of using QUADAS.
Methods
Assessment of the consistency and reliability of QUADAS
Three reviewers were asked to use QUADAS to independ-
ently rate the quality of 30 studies as part of a systematic
review on the diagnosis of peripheral arterial disease. One
QUADAS item, the use of an appropriate reference stand-
ard, was not assessed as studies were only included in the
review if they used a specified reference standard.
The three reviewers had different backgrounds and levels
of experience. Reviewer 1 had previously carried out sev-
eral diagnostic systematic reviews and had used QUADAS;
she also had a background in primary diagnostics.
Reviewer 2 was a new reviewer – this was the first review
that she had worked on, but she had previously worked in
primary diagnostics. Reviewer 3 was an experienced
reviewer who had worked on a number of systematic
reviews. This combination of reviewers with was chosen
to reflect the spectrum of likely QUADAS users.
A limited amount of information specific to the diagnosis
of peripheral arterial disease was provided to help with
the scoring of QUADAS, this applied to items 1 (spectrum
composition), 4 (disease progression bias), and 12 (avail-
ability of clinical information). For all other items, the
guidelines on scoring provided in the QUADAS back-
ground document were briefly summarised [3]. Although
reviewers did have access to the background document
they were not specifically requested to read this or use it
when assessing study quality.
Our main interest was in the amount of agreement
between the rating of each reviewer and the consensus rat-
ing, calculated as the proportion of studies for which each
reviewer agreed with the consensus rating. In addition, we
also examined inter-observer variability by calculating the
kappa statistic. Both analyses were carried out for all
QUADAS items combined and for each individual item.
We chose to focus on the proportion of agreements
between reviewers and the final consensus, as kappas can
be misleading in certain circumstances [4].
Piloting QUADAS in ongoing reviews
Reviewers who had used QUADAS in their reviews com-
pleted a short structured questionnaire asking how they
used QUADAS and what their opinions of its usefulness
were. Details of the questionnaire are provided in Table 1.
A narrative synthesis was used to summarise results.
Results
Assessment of the consistency and reliability of QUADAS
Table 2 summarises the agreement between reviewers.
Agreement between reviewers 1 and 2 and the final con-
sensus rating was very good at 91 and 90%, and was
Table 1: Questionnaire for evaluation of QUADAS
a) Review details
b) Content of the tool:
• Did QUADAS cover all important items?
• Were any QUADAS items omitted, added or modified?
c) Background document:
• Was the background document easy to understand?
• Were scoring instructions understandable?
• Should any items have been scored differently?
d) Technical points
• How long did it take to complete QUADAS?
• Was inter-rater reliability assessed?
e) Overall conclusions
• Reviewers were asked to rate coverage, ease of use, clarity of instructions, and validity (whether QUADAS helped to distinguish between 
studies of different qualities) on a five point scale
• Would you us QUADAS again?
f) Additional questions
• How were the results of quality incorporated into the review?
• Was a training session organised to ensure reviewers applied the tool consistently?
• Reviewer details, including age, experience, professional background
• Have you previously been involved in the quality assessment of studies included in a systematic review?
g) Final commentsBMC Medical Research Methodology 2006, 6:9 http://www.biomedcentral.com/1471-2288/6/9
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Table 2: Overall agreement between reviewers and agreement with consensus for each of the QUADAS items and for all items 
combined
QUADAS item Agreement with consensus diagnosis (%) (95% 
confidence interval)
Reviewer variability 
(κ) (95% confidence 
interval)
12 3
All items 
combined
91 (88–94) 90 (86–93) 85 (81–89) 0.66 (0.63 to 0.67)
1 Was the spectrum of patients representative of the 
patients
who will receive the test in practice? (spectrum 
composition)*
90 (73–98) 87 (69–96) 83 (65–94) 0.73 (0.60 to 0.76)
2 Were selection criteria clearly described? (selection 
criteria)
90 (73–98) 83 (65–94) 73 (54–88) 0.55 (0.33 to 0.61)
3 Is the reference standard likely to correctly classify
the target condition? (reference standard)*
4 Is the time period between reference standard and 
index
test short enough to be reasonably sure that the 
target condition
did not change between the two tests? (disease 
progression bias)*
87 (69–96) 90 (73–98) 83 (65–94) 0.68 (0.63 to 0.86)
5 Did the whole sample or a random selection of the 
sample,
receive verification using a reference standard of 
diagnosis? (partial verification)
87 (69–96) 90 (73–98) 93 (78–99) 0.27(-0.06 to 0.39)
6 Did patients receive the same reference standard 
regardless
of the index test result? (differential verification)
97 (83–100) 97 (83–100) 97 (83–100) 0.31 (-0.01 to 0.46)
7 Was the reference standard independent of the
index test (i.e. the index test did not form
part of the reference standard)? (incorporation bias)
100 (88–100) 100 (88–100) 93 (78–99) -0.02 (-0.03 to -0.01)
8 Was the execution of the index test described
in sufficient detail to permit replication of the test? 
(index test execution)
97 (83–100) 100 (88–100) 87 (69–96) 0.60 (0.33 to 0.73)
9 Was the execution of the reference standard 
described
in sufficient detail to permit its replication?
(reference standard execution)
93 (78–99) 93 (78–99) 93 (78–99) 0.81 (0.60 to 0.87)
10 Were the index test results interpreted
without knowledge of the results of the reference 
standard?
(test review bias)
90 (73–98) 87 (69–96) 97 (83–100) 0.55 (-0.04 to 0.75)
11 Were the reference standard results interpreted 
without
knowledge of the results of the index test?
(reference standard review bias)
93 (78–99) 93 (78–99) 93 (78–99) 0.68 (0.46 to 0.76)
12 Were the same clinical data available when test
results were interpreted as would be
available when the test is used in practice? (clinical 
review bias)*
90 (73–98) 93 (78–99) 50 (31–69) 0.18 (-0.13 to 0.36)
13 Were uninterpretable/ intermediate test results 
reported?
(uninterpretable test results)
83 (65–94) 70 (50–85) 87 (69–96) 0.32 (0.18 to 0.44)
14 Were withdrawals from the study explained?
(withdrawals)
90 (73–98) 83 (65–94) 80 (61–92) 0.38 (0.33 to 0.51)
* Items for which review specific details were added to QUADAS
+The item relating to reference standard was not assessed for this reviewBMC Medical Research Methodology 2006, 6:9 http://www.biomedcentral.com/1471-2288/6/9
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slightly lower (85%) for reviewer 3. Overall reviewer vari-
ability was good [5] with a kappa of 0.65.
Agreement between reviewers and the final consensus rat-
ing was over 80% for all but four items: selection criteria,
availability of clinical information, uninterpretable test
results and withdrawals. The poor agreement for the avail-
ability of clinical information was related to reviewer 3
who had a very poor level of agreement (50%) with the
final consensus rating; the other reviewers showed over
90% agreement with the final consensus. This suggests
that reviewer 3 was interpreting this item differently to the
other reviewers. The other three items, selection criteria,
uninterpretable results and withdrawals, showed moder-
ate agreement between each reviewer and the consensus
rating suggesting that there may be difficulties in applying
these items.
Piloting QUADAS in ongoing reviews
Twenty reviewers used QUADAS in their reviews and pro-
vided feedback via the structured questionnaire (Table 3).
Fifteen reviewers came from the UK, two from Australia,
two from the Netherlands, and one from Switzerland. Of
those from the UK, seven were employees of the Centre
for Reviews and Dissemination (CRD), which is where
some of the researchers who developed QUADAS were
based. The topics covered by the reviews included the
diagnosis of: tuberculosis, urinary tract infection in chil-
dren, haematuria, Dengue fever, prostate cancer, shoulder
pain, epilepsy seizure focus, angina and myocardial inf-
arction, infected diabetic foot ulcers, bacterial infections,
lumbar fusion, multiple sclerosis, and osteoporosis. Diag-
nostic tests under evaluation included laboratory tests,
imaging and physical examination. The number of studies
included in the reviews ranged from 1 to 208 (median
28).
Content of tool
The feedback from 20 reviewers on the content of the tool
was generally positive: eighteen reviewers thought that
QUADAS covered all important items, seventeen did not
omit any items, sixteen did not add any items, and nine-
teen did not modify any items.
Two reviewers thought that QUADAS did not cover all
important items, one felt that it did not adequately cover
population characteristics (description of spectrum, age,
setting, prevalence), that questions regarding therapy, the
positivity threshold of test results, and study design
should have been included as separate items. These com-
ments were mainly related to the desire to have informa-
tion on these items so that they could be explored in
subgroup analysis. The other reviewer thought that the
tool should cover whether data could be extracted into a
2 × 2 table.
Three reviewers omitted items from QUADAS. One stated,
"on occasions there were no withdrawals". One reviewer
omitted items on: reference standard, disease progression
bias, partial verification bias, differential verification bias
and incorporation bias as these were not applicable to the
topic area because there was no reference standard (the
review was on prostate biopsies). The other reviewer omit-
ted the item relating to disease progression bias as this did
not apply to studies included in their review. Another
reviewer stated that they did not omit any items but that
as most of the studies included in their review were diag-
nostic case control studies, items on the availability of
clinical information and withdrawals were difficult to
answer, and in most cases the issue of follow-up was not
relevant.
Four reviewers added items to QUADAS: one added clini-
cally relevant items specific to their review, one added
"Do you have plans to characterise data which are unsuit-
able for primary analysis?", one added "Was the raw data
available?" and one added a number of items relating to
the availability of 2 × 2 data, confidence intervals, a
description of the index and reference tests and a descrip-
tion of the test threshold.
One reviewer modified the items on uninterpretable
results and withdrawals to add a "not appropriate"
response. She stated that if there were no uninterpretable
test results it was unclear how to rate this item.
Background document
All but one reviewer found the background document
easy to understand, two did not understand the scoring
guidelines, and one reviewer thought that the items con-
cerning differential and partial verification bias should
have been scored differently. One reviewer found the item
on disease progression bias difficult to understand. How-
ever, this difficulty appeared to be related to how to score
this item specifically for their review rather than a prob-
lem with the instructions provided in the background
document. Two reviewers stated that they added topic
specific information to the background document to help
determine exactly how to score items for their review.
Despite efforts to keep the wording of QUADAS simple to
increase international applicability, two non-native Eng-
lish speakers had some difficulty in understanding the
QUADAS background document. They found the item on
the availability of clinical information difficult to under-
stand and did not know what was meant by uninterpreta-
ble or indeterminate data or results, and felt that the
background document did not clarify this. In future revi-
sions, clarity of phrasing will be a key consideration.BMC Medical Research Methodology 2006, 6:9 http://www.biomedcentral.com/1471-2288/6/9
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The reviewer who thought items should have been scored
differently felt that the items relating to verification bias
should have been formulated differently and suggested
"was verification bias avoided? (i.e. did the whole sample
or a random selection of the sample receive verification
using a reference standard)".
Technical points
The time taken to complete QUADAS ranged from less
than 10 minutes to over an hour. Five reviewers reported
that it took them <10 minutes, five that it took 10–15
minutes, seven that it took 15 to 30 minutes, two that it
took 30 to 60 minutes and one that it took more than an
hour. Some of the reviewers included the time to read the
whole paper and carry out data extraction and completing
QUADAS in this time, whereas others only included the
time taken to complete QUADAS. None of the reviewers
assessed inter-rater reliability.
Overall conclusions
Reviewers' ratings of QUADAS for coverage, ease of use,
clarity of instructions and validity were generally good,
especially for coverage, which was rated as good or very
good by all reviewers, and ease of use, which was rated as
at least average by all reviewers. One reviewer rated the
clarity of instructions and the validity of QUADAS as
being poor; she had earlier stated that she did not under-
stand the instructions for scoring QUADAS. She also felt
the studies in her review were of fairly poor quality but
still fulfilled at least half the QUADAS items. All reviewers
stated that they would use QUADAS again, although one
stated that she may not use all 14 items next time and
another stated that this was because there is currently no
better tool available.
Additional comments
A major theme in reviewers' additional comments related
to the poor quality of reporting of primary studies and the
fact that this often limits the quality assessment. Another
theme was that it is important to have an understanding
of the clinical context while scoring some of the items.
One reviewer suggested that it might be helpful to group
the questionnaire using subheadings such as "general",
"reference standard", and "index test". Another comment
was that initial training on how to use the tool would be
helpful.
Discussion
Principal findings
This evaluation has shown good agreement between
reviewers and the final consensus rating for most QUA-
DAS items and very positive feedback from reviewers who
have used QUADAS. Two items, uninterpretable results
and withdrawals, were found to be problematic. There
was poorer agreement among reviewers and between
reviewers and consensus for these items than for other
items; feedback from reviewers also suggested problems
with these items. One reviewer suggested that this might
be because it is difficult to know what to do it if it is
unclear if there are any uninterpretable results or with-
drawals. Our own use of QUADAS supports this: we have
found it very difficult to know how to score this item if the
study does not report whether there were any uninterpret-
able results/withdrawals, and if all patients who entered
the study appear to be accounted for. In such situations it
is often unclear whether the study authors simply
excluded uninterpretable results or withdrawals from
their reports, or if there truly were no uninterpretable
results or withdrawals. We have handled this problem by
giving more explicit instructions for scoring these QUA-
DAS items: we have stated that they should be scored as
yes if it appears that all patients who were entered into the
study completed the study.
The assessment of inter-rater reliability also highlighted
possible problems with the items on the availability of
clinical information and selection criteria. The item on
clinical information is very specific to each review and it is
therefore essential that clear guidelines on scoring this
item be provided, outlining exactly what information
should be available to the person interpreting the results
of the index test. This definition should be agreed a priori.
This was done for the review used for this evaluation and
is reflected in the very high levels of agreement between
two of the reviewers and the final consensus. It is unclear
why the third reviewer showed much poorer agreement
(50%) with the final consensus rating. It is unclear why
the item on selection criteria showed poorer agreement
with the consensus rating. This item was not highlighted
as problematic in the feedback from reviewers. It may be
related to the fact that no review specific information was
provided for this item.
All additional items suggested for inclusion in QUADAS
were considered as part of the development of QUADAS
but were items that were not selected by the panel of
experts for inclusion in the final tool. One of the items
suggested for inclusion, the item relating to the threshold
for the index test could be covered as part of item 8
(description of index test details). This is something to
consider including in the guidelines for scoring this item
when making guidelines specific to your review.
There was substantial variation in the time taken to com-
plete QUADAS, ranging from less than 10 minutes to over
1 hour. This may be explained by the fact that some
reviewers counted the time taken for the whole process of
data extraction, including reading the paper, whereas oth-
ers only counted the time taken to complete QUADAS.
Despite this, half the reviewers took less than 15 minutesB
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Table 3: Summary of responses to the questionnaire on reviewers' experience of using QUADAS
Reviewer 
Number
Coverage? Omit 
items?
Add 
items?
Modify 
item?
Easy to 
understand?
Scoring? Different 
scoring?
Time to 
complete 
(minutes)
Inter-
rater 
reliability
?
Coverage* Ease of 
use*
Clarity of 
instruction*
Validity* Use 
again?*
1 + - + - + + - 30–60 - 5 3 5 5 +
2+ - - + + + - < 1 0 - 4 4 3 4 +
3+ + - - + + - < 1 0 - 4 4 5 3 +
4 + - - - + + - 30–60 - 4 4 4 4 +
5 + - - - + + - 15–30 - 5 4 5 5 +
6 + - - - + + - 15–30 - 5 3 4 4 +
7 + - - - + - - 15–30 + 4 4 2 2 +
8 + - - - + - - 15–30 + 4 4 3 3 +
9- - + - + + + > 6 0 - 4 5 5 4 +
10 + - - - + + - <10 - 5 5 5 5 +
11 + - + - + + - 15–30 - 4 3 4 3 +
12 - - - - + + - 15–30 - 5 3 5 3 +
13 + + + - - - - 10–15 - 4 3 3 5 +
14 + + - - + + - 10–15 - 4 4 4 4 +
15 + - - - + + - 10–15 - 5 4 4 4 +
16 + - - - + + - 10–15 - 4 3 4 4 +
17 + - - - + + - <10 - 4 4 4 4 +
18 + - - - + + - <10 - 5 5 5 3 +
19 + - - - + + - 10–15 - 4 4 4 4 +
20 + - - - + + - 15–30 - 5 4 5 4 +
*Each of these items were rated from 1–5 where 1 is strongly disagree (very poor) and 5 is strongly agree (excellent)BMC Medical Research Methodology 2006, 6:9 http://www.biomedcentral.com/1471-2288/6/9
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and 17/20 took less than half an hour to complete QUA-
DAS suggesting that QUADAS is relatively quick to com-
plete.
Strengths and weaknesses of the study
The major strength of this study is that we carried out a
detailed evaluation of QUADAS, which specifically
included the views and experience of users. We are una-
ware of any other quality assessment tools for diagnostic
accuracy studies that have undergone any process of eval-
uation.
Ideally, we would have liked to assess the "construct valid-
ity" of the tool – "the degree to which a test measures what
it claims, or purports, to be measuring" [6]. As QUADAS
aims to provide an indication of the quality of a study one
way to assess this would be to take a set of "high" quality
studies and a set of "low quality" studies and determine
whether QUADAS can distinguish between these. This is
known as "extreme groups" [6]. The problem with this
process is determining which studies are high quality and
which are low quality: there is no objective way of doing
this. In addition, a systematic review is likely to include
studies covering a range of quality. A quality assessment
tool needs to be able to distinguish subtle differences
across this full range of study quality, not just the
extremes. We therefore decided against this method of
evaluation.
Unanswered questions and future research
We originally proposed to carry out a meta-epidemiolog-
ical regression analysis to investigate the association of
individual QUADAS items with estimates of test perform-
ance. However, due to limited time and resources such an
evaluation was not feasible. This is an area where future
research would be beneficial. The Cochrane Collabora-
tion is planning to extend its database to include diagnos-
tic test accuracy reviews and is in the process of producing
a handbook providing guidelines for the conduct of such
reviews. The recommendations on quality assessment
include a modified version of QUADAS (items 2, 8 and 9,
the items relating to reporting rather than quality have
been removed), and this will be built into the new
Cochrane software. All diagnostic reviews included in the
new Cochrane Database will therefore include an assess-
ment of QUADAS with the results entered into the Review
Manager Software in a structured way. In the future, once
a number of Cochrane Test Accuracy Reviews have been
completed, a meta-epidemiological regression analysis
can be pursued.
Conclusions – Suggestions for modifications to 
QUADAS
We do not feel that major modifications to the content of
QUADAS itself, in terms of items included, are necessary.
However, the evaluation highlighted particular difficulties
in scoring the items on uninterpretable results and with-
drawals. We therefore recommend that the guidelines for
scoring these items in the QUADAS background docu-
ment be modified as shown in Table 4. In addition, we
would like to highlight the importance of tailoring the
guidelines for scoring items to each particular review, and
of ensuring that all reviewers are clear on how studies
should be scored for each of the items. It is not possible to
provide a generic description of what should be consid-
ered an "appropriate patient spectrum", or what should
be considered an "appropriate reference standard". It is
therefore essential that all reviewers using QUADAS care-
fully consider how each individual item should be
applied to their review and adapt the background docu-
ment to make the guidelines for scoring specific to their
review. This should be done in close collaboration with a
clinical expert in the area of the review. Reviewers should
also carefully consider whether all QUADAS items are rel-
evant to their review, and also whether there are addi-
tional quality items not included in QUADAS which may
Table 4: Proposed modifications to the QUADAS background document*
13. Were uninterpretable/intermediate test results reported?
c. How to score this item
If it is clear that all test results, including uninterpretable/indeterminate/intermediate are reported then this item should be scored as "yes". If the 
authors do not report any uninterpretable/indeterminate/intermediate results, and if results are reported for all patients who 
were described as having been entered into the study then this item should also be scored as "yes". If you think that such results 
occurred but have not been reported then this item should be scored as "no". If it is not clear whether all study results have been reported then 
this item should be scored as "unclear".
14. Were withdrawals from the study explained?
c. How to score this item
If it is clear what happened to all patients who entered the study, for example if a flow diagram of study participants is reported, then this item 
should be scored as "yes". If the authors do not report any withdrawals and if results are available for all patients who were reported 
to have been entered into the study then this item should also be scored as "yes". If it appears that some of the participants who 
entered the study did not complete the study, i.e. did not receive both the index test and reference standard, and these patients were not 
accounted for then this item should be scored as "no". If it is not clear whether all patients who entered the study were accounted for then this 
item should be scored as "unclear".
* Proposed changes are highlighted in bold
*Each of these items were rated from 1–5 where 1 is strongly disagree (very poor) and 5 is strongly agree (excellent)Publish with BioMed Central    and   every 
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be of importance to their topic area and which they
should assess as part of their review. Consensus should be
established on all of these issues before starting the qual-
ity assessment. Lastly, an improvement in the quality of
reporting, by endorsing the standards for reporting of
diagnostic accuracy studies, the STARD initiative [7],
should occur. This will allow reviewers to assess study
quality rather than the quality of reporting.
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